Vamil Divan
Stock Analyst at Guggenheim
(4.64)
# 176
Out of 4,945 analysts
230
Total ratings
65.43%
Success rate
16.12%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Buy | $216 → $227 | $201.47 | +12.67% | 27 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $164 → $167 | $174.42 | -4.25% | 16 | Jul 17, 2025 | |
| PROK ProKidney | Maintains: Buy | $6 → $7 | $2.37 | +195.36% | 2 | Jul 14, 2025 | |
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $7.33 | +91.00% | 1 | Jun 16, 2025 | |
| SVRA Savara | Maintains: Buy | $9 → $8 | $2.70 | +196.30% | 1 | May 28, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $289.33 | -0.46% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $88.74 | -3.09% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $11.16 | +25.45% | 1 | May 8, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $60 | $4.41 | +1,260.54% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $82.71 | +39.04% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $18.05 | +160.39% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $24.64 | +25.81% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.12 | +220.51% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $25.16 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $21.97 | +177.65% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $122.87 | -17.80% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.90 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.57 | +4,475.85% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.85 | +964.96% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.97 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $25.13 | -24.39% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $131.62 | -25.54% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $28.63 | +18.76% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.71 | +484.80% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $109.39 | -55.21% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $660.49 | -46.10% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.28 | -17.58% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $14.39 | +970.19% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.51 | +130.41% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $32.31 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $17.21 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $5.00 | +200.00% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $47.85 | +27.48% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.94 | +5,209.28% | 3 | Jan 17, 2018 |
AbbVie
Aug 1, 2025
Maintains: Buy
Price Target: $216 → $227
Current: $201.47
Upside: +12.67%
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $164 → $167
Current: $174.42
Upside: -4.25%
ProKidney
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.37
Upside: +195.36%
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $7.33
Upside: +91.00%
Savara
May 28, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.70
Upside: +196.30%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $289.33
Upside: -0.46%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $88.74
Upside: -3.09%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $11.16
Upside: +25.45%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.41
Upside: +1,260.54%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $82.71
Upside: +39.04%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $18.05
Upside: +160.39%
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $24.64
Upside: +25.81%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.12
Upside: +220.51%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $25.16
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $21.97
Upside: +177.65%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $122.87
Upside: -17.80%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $13.90
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.57
Upside: +4,475.85%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.85
Upside: +964.96%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.97
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $25.13
Upside: -24.39%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $131.62
Upside: -25.54%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $28.63
Upside: +18.76%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.71
Upside: +484.80%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $109.39
Upside: -55.21%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $660.49
Upside: -46.10%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.28
Upside: -17.58%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $14.39
Upside: +970.19%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.51
Upside: +130.41%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $32.31
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $17.21
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $5.00
Upside: +200.00%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $47.85
Upside: +27.48%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.94
Upside: +5,209.28%